CBLL · Ceribell, Inc.
Market Cap
$910.71M
Shares
38.38M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$89.06M
+36.1%
FY2025
Net Income
-$53.41M
-32%
FY2025
Gross Margin
87.89%
+1.2pp
FY2025
Operating Margin
-65.57%
-4.9pp
FY2025
Diluted EPS
-$1.46
+56.9%
FY2025
Operating Cash Flow
-$40.81M
-16.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| $114M – $117M | $101.96M | $89.06MG | $65.44MG | $45.23M | |
| — | $11.32M | $10.79M | $8.69M | $7.06M | |
| — | $90.65M | $78.27M | $56.75M | $38.16M | |
| — | — | 87.89% | 86.72% | 84.38% | |
| — | $22.95M | $19.14M | $13.56M | $9M | |
| — | $84.43M | $73.08M | $49.06M | $38.92M | |
| — | $53.23M | $44.45M | $33.84M | $20.29M | |
| — | $1.25M | $1.34M | $1.14M | $847K | |
| — | $160.61M | $136.68M | $96.46M | $68.2M | |
| — | -$69.97M | -$58.4M | -$39.71M | -$30.04M | |
| — | — | -65.57% | -60.68% | -66.43% | |
| — | -$68.72M | -$57.06M | -$38.57M | -$29.19M | |
| — | $1.81M | $1.89M | $1.99M | $2.1M | |
| — | $5.79M | $6.88M | $2.74M | $2.64M | |
| — | -$66M | -$53.41M | -$40.46M | -$29.45M | |
| — | — | $0 | $0 | $11K | |
| — | -$66M | -$53.41M | -$40.46M | -$29.46M | |
| — | — | -59.97% | -61.82% | -65.15% | |
| — | -$66.09M | -$53.25M | -$40.46M | — | |
| USD/shares | — | -$1.75 | -$1.46 | -$3.39 | -$5.56 |
| USD/shares | — | -$1.75 | -$1.46 | -$3.39 | -$5.56 |
| shares | — | — | 36.54M | 11.95M | 5.3M |
| shares | — | — | 36.54M | 11.95M | 5.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.84×
EV/EBIT
—
Peer median 25.25×
P/E (TTM)
—
Peer median 24.50×
Peer medians compare against the 64 similar-size Medical Devices companies (of 139 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Product | $67,335,000 | $50,079,000 | $34,568,000 |
| Subscription | $21,728,000 | $15,365,000 | $10,657,000 |
Key facts
CIK
1861107
CUSIP
15678C102
13F (30d)
106 filings
104 filers
Visit website
Investor relations